Promidis Srl has presented results from preclinical evaluations of potent capsid assembly modulators (CAMs) to prevent abnormal accumulation of empty capsids and associated T-cell-mediated liver injury.
“We look at Japan with some envy with what they’ve been able to achieve and their approach to regenerative medicine, which has been supported significantly by their federal government,” said Silvio Tiziano, CEO of the Center for the Commercialization of Regenerative Medicine Australia, during the recent Ausbiotech conference in Perth.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Nephrology Kidney Week including: Boehringer, Chinook, Eli Lilly, Horizon, Ionis, Lexicon, Vera.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer Annual Meeting including: Affimed, Compugen, Genenta, Geneos, Hummingbird, Iovance, Nextcure, Nouscom, Oncolytics.
New and updated preclinical and clinical data presented by biopharma firms at the American Heart Association Scientific Sessions including: Amgen, Incarda, Innovent, Lexicon, Renibus, Silence.
New and updated preclinical and clinical data presented by biopharma firms at the AASLD Liver Meeting, including: 89bio, Albireo, Ascentage, Gannex, Seal Rock, Vaccitech, Vir.
New and updated preclinical data presented at the Society for Immunotherapy of Cancer's Annual Meeting
in Boston, by: Actym, Calidi, Cantargia, Cytovia, Enara Bio, Immunome, Leap, Lyell Immunopharma, TCR2.
Dimethylfumarate (DMF) is largely used for treating multiple sclerosis (MS), but about 61% of DMF-treated patients develop lymphopenia, with its consequent associated risks. Biomarkers for monitoring treatment efficacy with DMF in patients with MS would be helpful in this field.
RSS
